Palisade Bio (PALI) Non-Current Assets (2010 - 2026)
Palisade Bio (PALI) reported Non-Current Assets of $72000.0 for Q1 2026, down 76.24% year-over-year from $303000.0 in Q1 2025, and down 41.46% on a QoQ basis from $123000.0 in Q4 2025.
Palisade Bio (PALI) has 17 years of Non-Current Assets data on file, last reported at $72000.0 in Q1 2026.
- Quarterly Non-Current Assets fell 76.24% year-over-year to $72000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $560000.0 (down 67.33% YoY) and the FY2025 annual result came in at $123000.0, down 68.13% from the prior year.
- Non-Current Assets retreated to $72000.0 in Q1 2026 per PALI's latest filing, from $123000.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $1.1 million in Q3 2022 and bottomed at $72000.0 in Q1 2026.
- The 5-year median for Non-Current Assets is $466000.0 (2024), against an average of $523000.0.
- The widest annual swing landed in 2023, when Non-Current Assets jumped 935.87%; it then plunged 76.24% in 2026.
- Tracing PALI's Non-Current Assets over 5 years: stood at $1.0 million in 2022, then declined by 29.71% to $724000.0 in 2023, then slumped by 46.69% to $386000.0 in 2024, then slumped by 68.13% to $123000.0 in 2025, then slumped by 41.46% to $72000.0 in 2026.
- Per Business Quant, the three latest PALI Non-Current Assets figures stand at $72000.0 (Q1 2026), $123000.0 (Q4 2025), and $145000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | 72,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 72,000.00 |
| Dec 31, 2025 | 123,000.00 |
| Sep 30, 2025 | 145,000.00 |
| Jun 30, 2025 | 220,000.00 |
| Mar 31, 2025 | 303,000.00 |
| Dec 31, 2024 | 386,000.00 |
| Sep 30, 2024 | 466,000.00 |
| Jun 30, 2024 | 559,000.00 |
| Mar 31, 2024 | 639,000.00 |
| Dec 31, 2023 | 724,000.00 |
| Sep 30, 2023 | 801,000.00 |
| Jun 30, 2023 | 879,000.00 |
| Mar 31, 2023 | 953,000.00 |
| Dec 31, 2022 | 1.03 Mn |
| Sep 30, 2022 | 1.11 Mn |
| Jun 30, 2022 | 391,000.00 |
| Mar 31, 2022 | 92,000.00 |
| Dec 31, 2021 | 1.01 Mn |
| Sep 30, 2021 | 182,000.00 |
| Jun 30, 2021 | 224,000.00 |
| Mar 31, 2021 | 159,324.00 |
| Dec 31, 2020 | 2.12 Mn |
| Sep 30, 2020 | 178,104.00 |
| Jun 30, 2020 | 859,246.00 |
| Mar 31, 2020 | 896,828.00 |
| Dec 31, 2019 | 937,008.00 |
| Sep 30, 2019 | 977,211.00 |
| Jun 30, 2019 | 813,607.00 |
| Mar 31, 2019 | 867,426.00 |
| Dec 31, 2018 | 1.18 Mn |
| Sep 30, 2018 | 1.21 Mn |
| Jun 30, 2018 | 1.32 Mn |
| Mar 31, 2018 | 1.34 Mn |
| Dec 31, 2017 | 1.44 Mn |
| Sep 30, 2017 | 1.48 Mn |
| Jun 30, 2017 | 1.58 Mn |
| Mar 31, 2017 | 1.56 Mn |
| Dec 31, 2016 | 1.70 Mn |
| Sep 30, 2016 | 1.76 Mn |
| Jun 30, 2016 | 1.46 Mn |
| Mar 31, 2016 | 1.46 Mn |
| Dec 31, 2015 | 1.52 Mn |
| Sep 30, 2015 | 1.58 Mn |
| Jun 30, 2015 | 1.65 Mn |
| Mar 31, 2015 | 1.65 Mn |
| Dec 31, 2014 | 1.68 Mn |
| Sep 30, 2014 | 1.71 Mn |
| Jun 30, 2014 | 1.79 Mn |
| Mar 31, 2014 | 1.81 Mn |
| Dec 31, 2013 | 1.79 Mn |
| Sep 30, 2013 | 1.84 Mn |
| Jun 30, 2013 | 1.83 Mn |
| Mar 31, 2013 | 1.87 Mn |
| Dec 31, 2012 | 1.10 Mn |
| Sep 30, 2012 | 1.08 Mn |
| Jun 30, 2012 | 1.13 Mn |
| Mar 31, 2012 | 1.06 Mn |
| Dec 31, 2011 | 1.07 Mn |
| Sep 30, 2011 | 1.04 Mn |
| Jun 30, 2011 | 971,253.00 |
| Dec 31, 2010 | 761,113.00 |